COGNIT-MS: Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS

Sponsor
University Hospital of Mont-Godinne (Other)
Overall Status
Recruiting
CT.gov ID
NCT05510817
Collaborator
Saint-Luc University Hospital (Other)
50
1
1
48
1

Study Details

Study Description

Brief Summary

This prospective study combining non conventional MRI techniques, neuropsychological screening tools, and a neurophysiological work-up using a sensitive and validated battery, will evaluate the predictive value of these measures and will explore the changes of the cognitive scores from baseline.

Condition or Disease Intervention/Treatment Phase
  • Other: Multiparametric assessment
N/A

Detailed Description

Neurologists are in need for reliable and robust predictive factors enabling to predict disease evolution and treatment response. Moreover, recent studies suggested that the evolution patterns of cognitive status in MS could be mixed, contradicting the concept that cognitive impairment in MS will inevitably increase over time.

The main aim of this prospective study is to investigate the predictors of disease evolution, as measured by the EDSS score, using a multiparametric assessment combining neuropsychological tests (BCcogSEP battery), MRI-derived metrics (volumetric brain parameters, tractography, diffusion tensor imaging and fiber tracking), patient-reported outcome measures, and neurophysiological tools (multimodal evoked potentials), and to explore the evolutionary patterns of cognitive status (changes from baseline).

The investigators planned to include 50 patients with active RRMS and initiating a new disease-modifying treatment.

Yearly assessment starting from study inclusion will be performed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Multiparametric Clinical, Radiological, Neuropsychological, and Neurophysiological Assessment to Investigate Prognostic Factors for Disease Evolution and Treatment Response in MS: a Prospective Study.
Actual Study Start Date :
Jun 6, 2022
Anticipated Primary Completion Date :
Jun 6, 2026
Anticipated Study Completion Date :
Jun 6, 2026

Arms and Interventions

Arm Intervention/Treatment
Other: RRMS patients

RRMS patients initiating a new DMT

Other: Multiparametric assessment
neuropsychological assessment, PRO measures, non-conventional MRI metrics

Outcome Measures

Primary Outcome Measures

  1. Predictors of disease evolution [3 years]

    EDSS score worsening from baseline

  2. evaluation of evolutionary patterns of cognitive status (impaired vs non impaired)/changes from baseline [3 years]

    changes from baseline in cognitive scores

  3. baseline predictors of future cognitive impairment [3 years]

    abnormal cognitive performances based on cognitive scores (using BCcogSEP battery)

Secondary Outcome Measures

  1. alteration in strategic white matter tracts at the early stages of RRMS, in patients with and without cognitive impairment [3 years]

    fractional anisotropy

  2. predictive role of mEPS in predicting future disability [3 years]

    the Global Evoked Potential (GEP) score at study entry (baseline); EDSS score changes from baseline

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • active MS, according to the Lublin criteria

  • disease duration < 10 years before initiating or changing a disease-modifying therapies,

  • relapse- and steroid-free for at least 1 month before MRI acquisition

  • between 18-50 years old

  • having given informed consent

  • with no significant comorbidity other than MS or substance abuse that could interfere with cognitive performances

Exclusion Criteria:
  • progressive forms of MS

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU UCL Namur site Godinne Yvoir Namur Belgium

Sponsors and Collaborators

  • University Hospital of Mont-Godinne
  • Saint-Luc University Hospital

Investigators

  • Principal Investigator: Frédéric London, MD, University Hospital Mont-Godinne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Frédéric London, Principal Investigator, University Hospital of Mont-Godinne
ClinicalTrials.gov Identifier:
NCT05510817
Other Study ID Numbers:
  • B039202042775
First Posted:
Aug 22, 2022
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Frédéric London, Principal Investigator, University Hospital of Mont-Godinne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2022